UFP Technologies heads into its August 4 earnings release with a striking divergence: short sellers have been trimming positions even as the stock rallies, while options traders have just flipped to their most bullish stance in a year.
The options shift is the sharpest signal into this print. The put/call ratio has collapsed to 0.92 — the lowest reading of the past 52 weeks and almost 1.6 standard deviations below its 20-day average of 1.20. That's a meaningful reversal from a period when the ratio was consistently running between 1.10 and 1.68. Call demand has surged relative to puts at exactly the moment the stock surged 7.6% on the week to close at $267.53, recovering from a softer month that had left it down nearly 2% over 30 days. The setup looks like traders are leaning into the event rather than hedging against it.
Short interest tells a more cautious story on the bear side, but the positioning is still substantial. At 15.7% of the free float — roughly 1.21 million shares — UFPT carries a genuinely elevated short base, ranking in the 4th percentile of the ORTEX universe on short score rank (meaning most stocks have fewer shorts). That said, shorts have been quietly retreating: the position is down about 1.7% on the week and 1.4% over the past month, with the sharpest unwind concentrated in mid-July when shares outstanding short fell from near 1.29 million to around 1.21 million. Borrow conditions offer shorts no squeeze pressure — the cost to borrow is negligible at 0.56%, and availability has loosened to 115%, meaning more shares sit available to lend than are currently borrowed. The ORTEX short score of 71.6 remains elevated, reflecting the absolute level of the short base rather than any recent surge.
The institutional picture adds a quietly interesting footnote. Congress Asset Management added over 270,000 shares in the quarter ending June 30 — a near-65% increase in their position. Neuberger Berman also added 236,000 shares in the same period. Those are aggressive additions to a small-cap healthcare supplies name with a market cap that punches below the typical institutional radar. Insider flow, by contrast, has been uniformly in one direction: every trade logged in recent months has been a sale, including a $1.9 million disposal by Chairman and CEO R. Jeffrey Bailly on March 2. Net insider selling reached roughly $1.09 million over the past 90 days. That divergence — institutions buying while insiders sell — is a classic tension to watch heading into results.
Analyst coverage is thin and the most recent data is stale. Lake Street last raised its target to $289 (from $252) in August 2025, maintaining a Buy. The mean price target of $324.50 implies meaningful upside from current levels, though the consensus was struck in February 2026. Raymond James initiated at Market Perform in March 2025 with no target. The print will test whether the institutional conviction of Q2 buyers — and the call-heavy options posture built up in the last week — is supported by the revenue and margin trajectory that has driven this stock from the low $200s to nearly $270 in under a year.
See the live data behind this article on ORTEX.
Open UFPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
